Binary clinical trial risk - Phase 2/3 failure would likely render the company's primary asset worthless, with DLB representing a challenging endpoint given disease heterogeneity and placebo response variability
Competitive landscape evolution - multiple well-funded Alzheimer's/dementia programs (Eisai/Biogen's lecanemab, Eli Lilly's donanemab) establishing new standards of care that could marginalize p38α kinase mechanism
Regulatory pathway uncertainty for DLB indication given limited precedent approvals and FDA's evolving standards for neurodegenerative disease endpoints
Capital markets access risk - biotech IPO/follow-on windows close during risk-off periods, potentially forcing dilutive financings or asset sales
Mechanism-of-action risk - p38α kinase inhibition less validated than amyloid/tau targeting approaches that have achieved recent FDA approvals, creating investor skepticism
Larger pharma competitors with superior trial execution capabilities, patient recruitment networks, and regulatory relationships
Partnership leverage imbalance - if clinical data is positive but company lacks capital, forced to accept unfavorable licensing economics with big pharma partners
Cash runway risk - negative $36.2% FCF yield implies rapid cash consumption requiring financing within 12-18 months absent partnership capital
Equity dilution risk - likely need for multiple financing rounds before potential commercialization, diluting existing shareholders significantly
Going concern risk if Phase 2 data disappoints and capital markets remain closed - current ratio of 6.66 provides cushion but burn rate of approximately $40-50M annually (estimated) depletes resources quickly
StructuralCompetitiveBalance Sheet